Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases

Scalone, L; Ciampichini, Roberta; Fagiuoli, Stefano; Gardini, Ivan; Fusco, Francesco; Gaeta, Laura; Prete, Anna Del; Cesana, Giancarlo; Mantovani, LG

doi:10.1007/s11136-012-0318-0

Cited by 112 publications

(81 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The original EQ-5D-3L is a brief survey but its sensitivity to change has been questioned [2,12,13,15,19]. The new EQ-5D-5L survey has been validated in several patient populations for improving the sensitivity of HRQoL measurements [8,10,11,16,18], but has yet to be validated in a THA population. Our work suggests that with the addition of two response options, the five-level survey may be able to better measure change in HRQoL after surgery.…”

Section: Discussionmentioning

confidence: 99%

“…Our patient populations had some higher rates of inconsistent responses in certain dimensions than seen in other EQ-5D-5L survey test populations [10,11,16,18]. Unlike our method, the most common technique in the literature for comparing the three-and five-level surveys was to administer both surveys with demographic and additional survey questions in between the two versions during the same sitting [4,10,11,16,18].…”

Section: Survey Dimensionsmentioning

confidence: 99%

“…Unlike our method, the most common technique in the literature for comparing the three-and five-level surveys was to administer both surveys with demographic and additional survey questions in between the two versions during the same sitting [4,10,11,16,18]. As was seen by Janssen and collaborators [9] in 2008, this simultaneous administration of survey versions actually influenced patient responses leading to patients avoiding intermediate response options on the five-level survey if the three-level had been administered first.…”

Section: Survey Dimensionsmentioning

confidence: 99%

“…The five-level EQ-5D survey has been shown to have face validity, decrease ceiling effects, and increase discriminatory power in several patient populations over the three-level version [8,10,11,16,18]. However, the validity of this version has not, to our knowledge, been evaluated in patients undergoing THA.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty

Greene

Rader

Garellick

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background The EQ-5D is a generic health survey that can be used to compare improvement across different interventions, measure changes in health-related quality of life over time, or to explore cost-effectiveness among treatments, hospitals, or providers. The original EQ-5D survey has three response options for each of five health dimensions; however, with so few response options, ceiling and floor effects are problematic in some populations. A new version, called the EQ-5D-5L, was developed, which gives respondents five answer options (the ''5L'' refers to five response levels, which is in contrast to the original survey's three levels). However, the validity of this version has not, to our knowledge, been evaluated in patients undergoing total hip arthroplasty (THA). Questions/purposes The purposes of this study were (1) to characterize the redistribution of responses using the new version; (2) to describe the ceiling and floor effects in the current three-level version and identify whether the new EQ-5D-5L survey diminished these effects; and (3) to understand the convergent validity of the new version with the old and the EQ visual analog scale. Methods Both versions of the survey were administered either preoperatively or 1 to 6 years after THA, allowing at least 2 weeks between administrations. Responses to the two versions were compared to determine response redistribution properties, ceiling and floor effects, and convergent validity. Sample sizes were determined so that the study would have 90% power to detect a Spearman correlation over 0.7 when comparing the responses of the three-level survey with the five-level survey and allowing for a rate of 25% loss to followup.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Survey Dimensionsmentioning

confidence: 99%

Section: Survey Dimensionsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty

Greene

Rader

Garellick

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…49 Several studies have compared the EQ-5D-3L and the EQ-5D-5L in different countries in both general population samples and specific patient groups, but none of these has examined the two measures in critical care patients. [49][50][51][52][53][54][55][56][57][58][59] The aim of the present study was to compare EQ-5D-3L scores with EQ-5D-5L scores in critical care survivors in the UK. The sample for the present study comprised 359 patients treated at any of the 20 participating UK centres.…”

Section: Background and Aimsmentioning

confidence: 99%

The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost–utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up

Walsh

Stanworth

Boyd

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

on behalf of the UK ABLE trial investigatorsThe Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 09/144/51. The contractual start date was in September 2011. The draft report began editorial review in September 2016 and was accepted for publication in April 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the int...

show abstract

Reply

Petta¹,

Cabibbo²,

Cammà³

2015

Hepatology

View full text Add to dashboard Cite

Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases

Cited by 112 publications

References 18 publications

The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty

The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty

The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost–utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up

Reply

Contact Info

Product

Resources

About